Positive Outlook for Arcturus Therapeutics’ Vaccine Production and Distribution Spurs Buy Rating
Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on ARCT stock, giving a Buy rating on October 1.
Hosted on MSN3d
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus Therapeutics ARCT and partner CSL Seqirus, a renowned vaccine company, together reported encouraging results from a ...
Yahoo Finance18d
Here's Why Investors Should Invest in Arcturus Stock Now
Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...
Benzinga.com3d
Unveiling 3 Analyst Insights On Arcturus Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 3 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...
Investing2d
Arcturus shares hold with Buy rating on Japan vaccine progress
On Wednesday, H.C. Wainwright maintained a positive outlook on Arcturus Therapeutics (NASDAQ:ARCT), reiterating a Buy rating and a $63.00 price target for the stock. The firm's stance comes after ...
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT ...